Daré Bioscience, Inc.
DARE
$0.72
$0.011.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 187.50K | 152.50K | 1.02M | 2.30K | -21.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 187.50K | 152.50K | 1.02M | 2.30K | -21.20K |
| Cost of Revenue | 561.90K | 902.80K | -4.61M | 1.18M | 1.43M |
| Gross Profit | -374.30K | -750.30K | 5.63M | -1.17M | -1.45M |
| SG&A Expenses | 2.59M | 2.25M | 1.58M | 2.50M | 2.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.16M | 3.15M | 2.49M | 3.67M | 3.81M |
| Operating Income | -2.97M | -3.00M | -1.47M | -3.67M | -3.83M |
| Income Before Tax | -2.98M | -3.00M | -1.44M | -3.56M | -4.02M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.98M | -3.00M | -1.44M | -3.56M | -4.02M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.98M | -3.00M | -1.44M | -3.56M | -4.02M |
| EBIT | -2.97M | -3.00M | -1.47M | -3.67M | -3.83M |
| EBITDA | -2.40M | -2.44M | -936.90K | -3.19M | -3.37M |
| EPS Basic | -0.20 | -0.21 | -0.10 | -0.28 | -0.45 |
| Normalized Basic EPS | -0.13 | -0.13 | -0.06 | -0.17 | -0.28 |
| EPS Diluted | -0.20 | -0.21 | -0.20 | -0.28 | -0.45 |
| Normalized Diluted EPS | -0.13 | -0.13 | -0.06 | -0.17 | -0.28 |
| Average Basic Shares Outstanding | 14.89M | 14.52M | 14.29M | 12.76M | 8.87M |
| Average Diluted Shares Outstanding | 14.89M | 14.52M | 14.29M | 12.76M | 8.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |